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Human epidermal growth factor receptor 2 (HER2)–positive breast cancers are cur-
rently treated with trastuzumab, an anti-HER2 antibody. About 30% of these tumors 
express a group of HER2 fragments collectively known as p95HER2. Our previous 
work indicated that p95HER2-positive tumors are resistant to trastuzumab monother-
apy. However, recent results showed that tumors expressing the most active of these 
fragments, p95HER2/611CTF, respond to trastuzumab plus chemotherapy. To clarify 
this discrepancy, we analyzed the response to chemotherapy of cell lines transfected 
with p95HER2/611CTF and patient-derived xenografts (n = 7 mice per group) with 
different levels of the fragment. All statistical tests were two-sided. p95HER2/611CTF-
negative and positive tumors showed different responses to various chemothera-
peutic agents, which are particularly effective on p95HER2/611CTF-positive cells. 
Furthermore, chemotherapy sensitizes p95HER2/611CTF-positive patient-derived 
xenograft tumors to trastuzumab (mean tumor volume, trastuzumab alone: 906 mm3, 
95% confidence interval = 1274 to 538 mm3; trastuzumab+doxorubicin: 259 mm3, 95% 
confidence interval = 387 to 131 mm3; P < .001). This sensitization may be related to 
HER2 stabilization induced by chemotherapy in p95HER2/611CTF-positive cells.
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The receptor tyrosine kinase HER2 is over-
expressed in approximately 20% of breast 
cancers. HER2-positive breast cancers are 
currently treated with monoclonal antibod-
ies against the extracellular domain of the 
receptor, such as trastuzumab, in combi-
nation with different regimens of classical 
chemotherapy that interact, additively or 
synergistically, with the antibody (1). Despite 
its remarkable effectiveness, tumors fre-
quently become resistant to this combination 
and resume their malignant progression (2).
About 30% of HER2-positive breast 
cancers express a series of HER2 carboxy-
terminal fragments collectively known as 
HER2 CTFs or p95HER2 (3). An initial 
study showed that p95HER2-expressing 
tumors are resistant to the treatment with 
trastuzumab (4).
One of the p95HER2 fragments, the so-
called 100–115 kDa p95HER2 or 611CTF 
is highly oncogenic because it spontane-
ously homodimerizes into a constitutively 
active form (5). The current availability 
of specific antibodies allows the detec-
tion of p95HER2/611CTF in clinically 
relevant samples (6,7). Preliminary analy-
ses of samples from the GeparQuattro 
clinical trial showed, in contrast with 
Scaltriti et  al. (4), that the expression of 
p95HER2/611CTF was associated with 
better response to neoadjuvant therapy 
that included trastuzumab (8). A difference 
between these studies was that more than 
half (56%) of the patients included in the 
initial study were treated with trastuzumab 
alone (4). In contrast, patients from the 
GeparQuattro trial received trastuzumab 
plus anthracycline-taxane-based chemo-
therapy (8).
To investigate the effect of p95HER2/ 
611CTF expression on the response to 
chemotherapy, we used immunohisto-
chemistry, transcriptomic analysis, prolif-
eration assays, flow cytometry and confocal 
microscopy, as well as experiments with 
patient-derived xenograft mice. Written 
informed consent for the use of the sam-
ples was obtained from all patients who 
provided tissue. All statistical analyses were 
performed using GraphPad Prism version 
5.0 software. Differences between means 
were estimated using the Student’s t test. 
All statistical tests were two-sided. Data 
represent results from three or more inde-
pendent experiments. Additional details 
are given in the Supplementary Methods 
(available online).
First we determined the levels of 
p95HER2/611CTF (Figure 1A), as well 
as the subtype of breast cancer accord-
ing to the levels of expression of selected 
genes (Figure 1B), of a series of 54 HER2-
positive samples. Less than half (42.42%) 
of the p95HER2/611CTF-negative tumors 
were HER2-enriched (Figure 1C). In con-
trast, virtually all the p95HER2/611CTF-
positive samples expressed high levels of 
HER2 mRNA (Figure 1B), and most of 
them (80.95%) belonged to the HER2-
enriched subtype (Figure 1C). Of note, a 
recent report showed that, compared with 
other subtypes, HER2-enriched tumors 
tended to respond better to therapeutic 
regimens that include chemotherapy and 
trastuzumab (9). Furthermore, the per-
centage of cells expressing nuclear Ki-67 
was statistically significantly higher in 
p95HER2/611CTF-positive breast cancer 
samples (P = .021) (Figure 1D), and high 
levels of this proliferation marker predict 
response to chemotherapy (10).
The analysis of different breast cancer 
cell lines indicated that p95HER2/611CTF 
expression induces sensitivity to the 
anthracycline doxorubicin (Supplementary 
Figure  1, available online). To determine 
if there is an association between the 
expression of p95HER2/611CTF and an 
increased sensitivity to chemotherapy, we 
generated p95HER2/611CTF-express-
ing cells (Figure  1E). In agreement with 
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the high percentage of Ki-67-positive 
cells in p95HER2/611CTF-positive 
breast cancers (Figure  1D), expression 
of p95HER2/611CTF, alone or along 
with HER2, accelerated cell proliferation 
(P = .0056 alone, P < .001 in combination) 
(Figure 1F). In consonance with this result, 
p95HER2/611CTF statistically signifi-
cantly increased the sensitivity to doxo-
rubicin and the induction of apoptotic 
cell death (P < .001 for cells expressing 
HER2 and p95HER2/611CTF compared 
with those expressing HER2, after doxo-
rubicin treatment) (Figure  1G). Thus, 
p95HER2/611CTF-positive cells show 
a higher sensitivity to DNA-damaging 
chemotherapy compared with p95HER2/ 
611CTF-negative cells.
Figure  1. Characterization of p95HER2/611CTF-positive breast cancers 
and effect of p95HER2/611CTF expression on sensitivity to chemo-
therapy. A) Human epidermal growth factor receptor 2 (HER2) and 
p95HER2/611CTF protein expression were evaluated in a series of breast 
cancer samples by immunohistochemistry. Two representative exam-
ples are shown. Scale bar, 100 µm, in all panels. B) Unsupervised hierar-
chical clustering of the samples analyzed in A according to the levels of 
expression of 50 selected genes using the Counter platform. All tumors 
were assigned to an intrinsic molecular type of breast cancer (Luminal 
A, Luminal B, HER2-enriched, and Basal-like) (18). C) Percentage of 
p95HER2/611CTF-negative and p95HER2/611CTF-positive samples in 
each molecular type of breast cancer. D) The expression of the Ki-67 
proliferation marker was determined in the samples analyzed in A. Box 
plots show the percentage of Ki-67-positive cells in p95HER2/611CTF-
negative and -positive samples. Lower and higher whiskers indicate 10th 
and 90th percentiles, respectively; lower and higher edges of box indi-
cate 25th and 75th percentiles, respectively; the inner line in the box indi-
cates 50th percentile. p95HER2/611CTF-negative and -positive samples 
were compared using the two-sided Student’s t test. E) MCF10A cells 
stably transduced with an empty viral vector or the same vector encod-
ing HER2 or p95HER2/611CTF, individually or together, were lysed and 
the cell lysates analyzed by western blot with the indicated antibodies. 
The bands corresponding to HER2 and p95HER2/611CTF are indicated in 
the upper panel. Results are representative of three independent experi-
ments. F) The same cells as in (E) were seeded, and cell number was 
assessed at the indicated time points by the crystal violet staining assay. 
Error bars correspond to 95% confidence intervals of three independent 
experiments. P values were calculated using the two-sided Student’s 
t test;  ***P < .001. G) The same cell lines as in (E) were treated with 
different concentrations of doxorubicin for one week. Cell number was 
estimated with the crystal violet staining assay. The sub-G1 cell fraction 
was determined through cell cycle analysis, and it was expressed as 
percentages of the whole-cell population. Error bars correspond to 95% 
confidence intervals of three independent experiments, each contain-
ing triplicates. P values were calculated using the two-sided Student’s 
t test; ***P < .001. HER2 = human epidermal growth factor receptor 2.
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Figure  2. Effect of trastuzumab and doxorubicin on the growth of 
p95HER2/611CTF-negative and -positive patient-derived xenografts 
(PDXs) and effect of doxorubicin on human epidermal growth factor 
receptor 2 (HER2) levels in p95HER2/611CTF-negative and -positive 
cells. A) Patient-derived xenografts obtained from two HER2-positive 
breast cancers not expressing (upper panel) (PDX118) or expressing 
(lower panel) (PDX67) p95HER2/611CTF (11) were treated as indicated 
(n = 7 in each group). Error bars correspond to 95% confidence inter-
vals. P values were calculated using the two-sided Student’s t test; 
***P < .001 (PDX67; control mice vs mice treated with doxorubicin 
at days 12-19; mice treated with trastuzumab alone vs mice treated 
with trastuzumab plus doxorubicin at days 33-40). PDX118 and PDX67 
belong to the luminal B and HER2-enriched subgroups, according to 
the gene signatures described in Figure 1B. B) MCF10A cells express-
ing HER2 or HER2 and p95HER2/611CTF were analyzed by western 
blot. The signals corresponding to HER2 or phospho-HER2 (pHER2) 
were quantified. Error bars correspond to 95% confidence intervals 
of four independent experiments. P values were calculated using the 
two-sided Student’s t test. C) The same cells as in (B) were treated 
with 1µM lapatinib for 48 hours. Then, cells were analyzed by flow 
cytometry with antibodies against the extracellular domain of HER2. 
The results from three independent experiments are expressed as 
average fold increase relative to untreated control. Error bars corre-
spond to 95% confidence intervals of four independent experiments. 
P values were calculated using the two-sided Student’s t test. D) MCF7 
Tet-Off cells stably transfected with constructs encoding wild-type 
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To analyze the effect of chemotherapy 
in vivo, we used two recently established 
breast cancer patient-derived xenografts 
(PDXs) (11). Trastuzumab impaired the 
growth of the p95HER2/611CTF-nega-
tive PDX118 (mean tumor volume, trastu-
zumab: 298 mm3, 95% confidence interval 
(CI) = 459 to 137 vs control: 689 mm3, 
95% CI = 938 to 439, P = .037) (Figure 
2A, upper panel) while it did not affect the 
growth of the p95HER2/611CTF-posi-
tive PDX67 (mean tumor volume, day 40: 
906 mm3, 95% CI = 1274 to 538) (Figure 
2A, lower panel). Treatment with doxo-
rubicin slightly inhibited the growth of 
the p95HER2/611CTF-positive PDX67, 
although the effect was only statistically 
significant during a limited period of time 
(P = .014 at day 12, P = .048 at day 16, and 
P = .031 at day 19) (Figure 2A, lower panel). 
Unexpectedly, treatment with doxorubicin 
sensitized PDX67 to trastuzumab, showing 
that p95HER2/611CTF-positive tumors 
are targeted by the trastuzumab-doxoru-
bicin combination (mean tumor volume, 
day 40: 259 mm3, 95% CI = 387 to 131; P < 
.001) (Figure 2A, lower panel).
Treatment of cell cultures established 
from the PDXs with doxorubicin plus 
trastuzumab did not show any coop-
erative effect between the two drugs in 
vitro (Supplementary Figure 2, avail-
able online). This result indicated that, 
despite using NOD-SCID, which have 
impaired natural killer (NK) cell func-
tion, the effect observed in vivo (Figure 
2A) could be because of the known abil-
ity of trastuzumab to induce antibody-
dependent cell-mediated cytotoxicity 
(ADCC) (12,13). In fact, previous reports 
have shown ADCC in this immunodefi-
cient mouse strain (14).
Compared with the unphosphoryl-
ated form, active phosphorylated HER2 
is rapidly endocytosed and degraded. 
Accordingly, inhibition of the phospho-
rylation of HER2 leads to the accumula-
tion of HER2 at the cell surface and, as a 
consequence, to enhanced trastuzumab-
dependent cell-mediated cytotoxicity (15). 
The expression of p95HER2/611CTF 
was associated with reduced levels of the 
phosphorylated form of HER2 in differ-
ent cellular contexts (P = .009) (Figure 2B; 
Supplementary Figure 3, available online; 
see also phosphorylated HER2 in Figure 
1E), indicating that p95HER2/611CTF 
reduces the phosphorylation of full-length 
HER2 and, hence, stabilizes it. Analysis of 
cells expressing p95HER2/611CTF or, as 
control, a kinase-dead p95HER2/611CTF 
mutant, under the control of a promoter 
regulated by doxycycline, confirmed that 
p95HER2/611CTF increases the levels of 
full-length HER2 (P = .031) (Figure 2D). 
Furthermore, treatment with lapatinib, 
an inhibitor of the phosphorylation of 
HER2, statistically significantly increased 
the levels of cell surface HER2 in cells 
not expressing p95HER2/611CTF  (P = 
.030). In expressing cells, where the phos-
phorylation of HER2 is already inhibited 
by p95HER2/611CTF, lapatinib had lit-
tle effect on the level of cell surface HER2 
(Figure 2C).
Since the activation of HER2 and, 
hence, its stability can be modified by 
p95HER2/611CTF, we hypothesized that 
HER2 levels may be differentially affected 
in p95HER2/611CTF-positive and -nega-
tive cells by chemotherapy. Supporting 
this hypothesis, treatment with doxoru-
bicin resulted in increased levels of HER2 
in cells expressing p95HER2/611CTF 
but not in nonexpressing cells (P = .005) 
(Figure 2E). Concordant results were 
observed when analyzing the levels of cell 
surface HER2 (Figure 2F). Although the 
mechanism behind this differential effect 
is unknown, it is not likely because of a 
direct binding of doxorubicin to HER2. 
As expected, the increase of cell surface 
HER2 in p95HER2/611CTF-expressing 
cells (Figure 2F) was accompanied by an 
increase in trastuzumab-dependent cell-
mediated cytotoxicity (Figure 2G).
The very recent analysis of 
p95HER2/611CTF in samples of 
the NeoALTTO trial has shown that 
p95HER2/611CTF is also associated with 
a better response of breast cancers to tras-
tuzumab in combination with paclitaxel 
(16), a microtubule-stabilizing drug. The 
sensitivity of cell lines expressing different 
levels of p95HER2/611CTF shows that, 
as is the case with doxorubicin, the HER2 
fragment sensitizes to the treatment with 
paclitaxel. Further, paclitaxel also increased 
the levels of HER2 at the cell surface in 
p95HER2/611CTF-expressing cells but 
not in p95HER2/611CTF-negative cells 
(Supplementary Figure 4, available online).
The results presented here show 
that breast cancer cells expressing 
p95HER2/611CTF are effectively targeted 
by regimens including chemotherapy in 
combination with trastuzumab (scheme in 
Figure  2H). This is likely because of the 
higher sensitivity of p95HER2/611CTF-
positive cells to the chemotherapeutic 
agents and, in addition, because of the stabi-
lization of full-length HER2, which results 
in more effective ADCC. This study also 
had some limitations. Because of the diffi-
culty of establishing PDXs, we could only 
analyze two. The expansion of this analy-
sis would definitively confirm the effect of 
the expression of p95HER2/611CTF on 
the response to trastuzumab plus chemo-
therapy. In addition, evaluation of ADCC 
was performed only in cell lines expressing 
levels of p95HER2/611CTF higher than 
p95HER2/611CTF (upper blot) or p95HER2/611CTF bearing a mutation 
(K767) that inactivates its kinase domain (lower blot), p95HER2/611CTF 
KD, under the control of a doxycycline regulated promoter, were cul-
tured with or without doxycycline. Then, cells were lysed and cell 
lysates analyzed by western blot. The signal corresponding to full-
length HER2 was quantified from four independent experiments and 
averages and 95% confidence intervals are shown. P values were cal-
culated using the two-sided Student’s t test. E) The same cells as in 
(B) were treated with 1.25 nM doxorubicin for one week, lysed and 
cell lysates analyzed by western blot; the signals corresponding to 
full-length HER2 were quantified from three independent experi-
ments and expressed as average fold increase relative to untreated 
control ± SD. P values were calculated using the two-sided Student’s 
t test. F) The same cells as in (B) were treated with 1.25 nM doxoru-
bicin for one week and analyzed by flow cytometry with antibodies 
against the extracellular domain of HER2. Error bars correspond 
to 95% confidence intervals of four independent experiments. G) 
Antibody-dependent cell-mediated cytotoxicity (ADCC) was analyzed 
as described in (15), after treating target cells with or without 1.25 nM 
doxorubicin for one week. H) Schematic drawing showing the effect of 
the combination of trastuzumab and doxorubicin on p95HER2/611CTF-
negative cells (blue background) or p95HER2/611CTF-positive cells 
(red background). HER2 is represented by two big filled red circles 
linked by a broken line, the p95HER2/611CTF constitutively active frag-
ment is represented by a small filled red circle linked with a broken 
line to a big one. Treatment with doxorubicin induces apoptosis more 
efficiently in p95HER2/611CTF-positive cells and, additionally, destabi-
lizes phospho-HER2 and stabilizes HER2 in p95HER2/611CTF-negative 
and -positive cells, respectively. LC = loading control; HER2 = human 
epidermal growth factor receptor 2; ns = statistically non-significant
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those observed in tumor samples. Despite 
these limitations, these results reconcile 
previous apparently contradictory reports 
and indicate that p95HER2/611CTF is a 
useful biomarker for the efficacy of thera-
peutic regimens including trastuzumab and 
chemotherapy.
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